Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03011541 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Stem Cell Ophthalmology Treatment Study II

Study acronym: SCOTS2
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 31, 2026 to Jul 31, 2027
    • Study completion date: Jul 31, 2027 to Jul 31, 2028
    v27
  2. Primary completion date: Jul 31, 2025 to Jul 31, 2026
    • Study sites: 3 to 4
    • Study completion date: Jul 31, 2026 to Jul 31, 2027
    v26
  3. Primary completion date: Jul 2024 to Jul 31, 2025
    • Study completion date: Jul 2025 to Jul 31, 2026
    v25
  4. Primary completion date: Jul 2023 to Jul 2024
    • Study completion date: Jul 2024 to Jul 2025
    v24
  5. Re-verified, no change to tracked fieldsv23
Show 21 earlier versionsHide 21 earlier versions
  1. Primary completion date: Jan 2023 to Jul 2023v22 Show 4 more changesShow less
    • Study completion date: Jan 2024 to Jul 2024
    • Interventions: Arm 1 (Procedure), Arm 2 (Procedure), Arm 3 (Procedure) to Arm 1 (Procedure)
    • Eligibility criteria revised
    • Study arms: 3 to 1
  2. Re-verified, no change to tracked fieldsv21
  3. Primary completion date: Jan 2022 to Jan 2023
    • Study completion date: Jan 2023 to Jan 2024
    • Study sites revised (3)
    v20
  4. Publications: 7 to 11v19
  5. Site details revised at 1 of 3 sitesv18
  6. Site details revised at 1 of 3 sitesv17
  7. Primary completion date: Jan 2021 to Jan 2022
    • Study sites: 2 to 3
    • Study completion date: Jan 2022 to Jan 2023
    v16
  8. 3 versions Re-verified since Oct 25, 2019, no change to tracked fieldsv13-v15
  9. Primary completion date: Jan 2020 to Jan 2021
    • Study completion date: Jan 2021 to Jan 2022
    v12
  10. Study sites revised (2)
    • Publications: 5 to 7
    v11
  11. Re-verified, no change to tracked fieldsv10
  12. Study sites: 1 to 2v9
  13. 2 versions Re-verified since Feb 1, 2018, no change to tracked fieldsv7-v8
  14. Publications: 4 to 5v6
  15. Study description shortened, about 1 wordv5
  16. Study description expanded, about 1 wordv4
  17. Study sites: 2 to 1v3
  18. Site details revised at 1 of 2 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.
Trial Details
NCT Number NCT03011541
Lead Sponsor MD Stem Cells
Conditions
(from sponsor)		 Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease +10 more
Related terms Blindness, Cone Dystrophy, Cone-Rod Dystrophies, Doyne honeycomb retinal dystrophy, Eye Diseases, Geographic Atrophy, Glaucoma, Macular Degeneration, Neuromyelitis Optica, Optic Atrophy, Optic Atrophy, Autosomal Dominant, Optic Atrophy, Hereditary, Leber, Optic Nerve Diseases, Optic Nerve Injuries, Optic Neuropathy, Ischemic, Retinal Diseases, Retinal Dystrophies, Retinitis Pigmentosa, Stargardt Disease, Usher Syndromes, Vision Disorders, Vision, Low, Vitamin A Deficiency, Wet Macular Degeneration
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov